Voyager Therapeutics/$VYGR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Voyager Therapeutics
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Ticker
$VYGR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
172
ISIN
US92915B1061
Website
VYGR Metrics
BasicAdvanced
$168M
-
-$1.46
0.82
-
Price and volume
Market cap
$168M
Beta
0.82
52-week high
$9.55
52-week low
$2.65
Average daily volume
693K
Financial strength
Current ratio
6.098
Quick ratio
5.922
Long term debt to equity
12.675
Total debt to equity
15.4
Profitability
EBITDA (TTM)
-94.472
Gross margin (TTM)
-92.70%
Net profit margin (TTM)
-126.49%
Operating margin (TTM)
-147.89%
Effective tax rate (TTM)
-0.82%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-15.04%
Return on equity (TTM)
-27.61%
Valuation
Price to revenue (TTM)
2.632
Price to book
0.62
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-1.546
Free cash flow yield (TTM)
-64.69%
Free cash flow per share (TTM)
-196.65%
Growth
Revenue change (TTM)
-43.75%
Earnings per share change (TTM)
2,162.41%
3-year revenue growth (CAGR)
28.48%
10-year revenue growth (CAGR)
38.51%
3-year earnings per share growth (CAGR)
-7.95%
10-year earnings per share growth (CAGR)
-28.05%
What the Analysts think about VYGR
Analyst ratings (Buy, Hold, Sell) for Voyager Therapeutics stock.
VYGR Financial Performance
Revenues and expenses
VYGR Earnings Performance
Company profitability
VYGR News
AllArticlesVideos
Voyager Reports First Quarter 2025 Financial and Operating Results
GlobeNewsWire·1 month ago
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
GlobeNewsWire·2 months ago
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Voyager Therapeutics stock?
Voyager Therapeutics (VYGR) has a market cap of $168M as of June 20, 2025.
What is the P/E ratio for Voyager Therapeutics stock?
The price to earnings (P/E) ratio for Voyager Therapeutics (VYGR) stock is 0 as of June 20, 2025.
Does Voyager Therapeutics stock pay dividends?
No, Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Voyager Therapeutics dividend payment date?
Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders.
What is the beta indicator for Voyager Therapeutics?
Voyager Therapeutics (VYGR) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.